Alkermes Stock Slides as Full-Year Guidance Disappoints Investors

Shares of Alkermes plc (ALKS) fell more than 5% in pre-market trading after the company's full-year revenue forecast disappointed investors, overshadowing second-quarter results that surpassed Wall Street estimates.

Guidance Overshadows Q2 Beat

Alkermes reported its financial results for the second quarter of 2026 before the market opened, delivering a beat on both top and bottom lines. However, the positive quarterly performance was not enough to satisfy market expectations for the full year.

• Adjusted Earnings Per Share: $0.00, beating the consensus estimate of -$0.02.
• Q2 Revenue: $496 million, a 27% year-over-year increase that surpassed the forecast of $459 million.

Despite the strong quarter, the company reaffirmed its full-year 2026 revenue guidance. The midpoint of that guidance, at $1.785 billion, landed below the analyst consensus of $1.81 billion, signaling a potential slowdown that concerned investors.

Market Reaction and Context

Ad

The stock's sharp decline reflects its significant run-up prior to the earnings release. Shares had surged approximately 88% year-to-date, setting a high bar for the company's financial report and outlook. This elevated valuation made the stock vulnerable to profit-taking on any perceived weakness.

Adding to the pressure was a notable level of short interest, representing about 10.7% of the float. The combination of a crowded long trade and a guidance miss created a catalyst for the sell-off, as the stock was trading near its 52-week high of $55.67.

Analyst View and Business Drivers

Not all reaction was negative. Analysts at Piper Sandler raised their price target on Alkermes to $65 from $43 and maintained an Overweight rating, arguing the company remains undervalued. However, this optimistic view did not halt the pre-market decline.

The company's revenue beat was partly driven by contributions from its LUMRYZ franchise, which treats narcolepsy and was added through the acquisition of Avadel Pharmaceuticals. Nonetheless, the tempered full-year outlook remained the dominant factor for investors on Tuesday.